SIMBRINZA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, Nigeria, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug SIMBRINZA contains a combination of these active pharmaceutical ingredients (APIs):

1	Brinzolamide UNII 9451Z89515 - BRINZOLAMIDE
	Brinzolamide is an inhibitor of carbonic anhydrase II (CA-II). Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion resulting in a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.
	Read more about Brinzolamide
2	Brimonidine UNII 4S9CL2DY2H - BRIMONIDINE TARTRATE
	Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.
	Read more about Brimonidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SIMBRINZA Eye drops, suspension (eye drops)	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EC54		S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EC Carbonic anhydrase inhibitors
Discover more medicines within S01EC54

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10536M, 10547D
BR	Câmara de Regulação do Mercado de Medicamentos	526517050089107, 526517050089207
CA	Health Products and Food Branch	02435411
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1345-MEE-0915
EE	Ravimiamet	1657694, 1657706
ES	Centro de información online de medicamentos de la AEMPS	114933001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	387012, 472984
FR	Base de données publique des médicaments	64880296
GB	Medicines & Healthcare Products Regulatory Agency	249969
HK	Department of Health Drug Office	64944
IE	Health Products Regulatory Authority	50805
IL	מִשְׂרַד הַבְּרִיאוּת	7977
IT	Agenzia del Farmaco	043532011, 043532023
LT	Valstybinė vaistų kontrolės tarnyba	1073921, 1073922
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	126M2017
NG	Registered Drug Product Database	B4-9101
NL	Z-Index G-Standaard, PRK	120197
PL	Rejestru Produktów Leczniczych	100317780
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64462001
SG	Health Sciences Authority	15085P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504710175
US	FDA, National Drug Code	0065-4147, 0078-0904